GFP Antibody - BSA Free

Immunohistochemistry: GFP Antibody [NB100-1614]

GFP-Antibody-Immunohistochemistry-NB100-1614-img0018.jpg

Immunocytochemistry/ Immunofluorescence: GFP Antibody [NB100-1614]

Immunocytochemistry/Immunofluorescence: GFP Antibody [NB100-1614] - IF analysis of GFP in rat cortical culture (2 weeks old). ICC/IF image submitted by a verified customer review.

Immunocytochemistry/ Immunofluorescence: GFP Antibody [NB100-1614]

Immunocytochemistry/Immunofluorescence: GFP Antibody [NB100-1614] - LNCaP human prostate cancer cell line imaged after transfection with GFP expressing plasmid. ICC/IF image submitted by a verified customer review.

Immunocytochemistry/ Immunofluorescence: GFP Antibody [NB100-1614]

Immunocytochemistry/Immunofluorescence: GFP Antibody [NB100-1614] - Staining of a tissue section through the midbrain region of an adult mouse for GFP (green) and Tryptophan Hydroxylase-positive neurons (RED).

Immunohistochemistry-Paraffin: GFP Antibody [NB100-1614]

Immunohistochemistry-Paraffin: GFP Antibody [NB100-1614] - Pyramidal neurons in the hippocampal formation of a neonatal mouse brain. Tissue was paraformaldehyde-fixed (4%) and paraffin-embedded. GFP staining is in green in left panel.

Immunohistochemistry-Paraffin: GFP Antibody [NB100-1614]

Immunohistochemistry-Paraffin: GFP Antibody [NB100-1614] - Embyonic mouse brain section. GFP in green, DAPI in grey. IHC-P image submitted by a verified customer review.

Immunohistochemistry: GFP Antibody [NB100-1614]

GFP-Antibody-Immunohistochemistry-NB100-1614-img0017.jpg

Immunocytochemistry/Immunofluorescence: GFP Antibody [NB100-1614]

Comparison between GFP-immunoreactivity using NB100-1614 (left panel in red) and autofluorescence (right panel in green). In this case, the cortical neuron in this unfixed thick section was first photographed for GFP autofluorescence (left), and then the section was fixed (4% paraformaldehyde) and immunostained for GFP-immunoreactivity (1:1000 dilution) using Texas Red-goat anti-chicken IgY antibodies as a secondary. The same cell (left) was then identified. Far right: Western blot showing specific immunolabeling of the GFP protein.

Immunohistochemistry: Chicken Polyclonal GFP Antibody [NB100-1614] -

Immunohistochemistry: Chicken Polyclonal GFP Antibody [NB100-1614] - Chicken Polyclonal GFP Antibody on mouse cancer tissue. DAPI (Red) and Cytopastmic GFP stain (Green). Primary antibody dilution: 1:200 in a 200 um slice. Image from a verified customer review.

Immunohistochemistry-Frozen: Chicken Polyclonal GFP Antibody [NB100-1614] -

Immunohistochemistry-Frozen: Chicken Polyclonal GFP Antibody [NB100-1614] - Image depicting GFP in magenta and CD31 (Catalog # AF3628) in red. Tissue is a fixed frozen section of sciatic nerve obtained from a S100A4 GFP mouse. NB100-1614 was diluted 1 in 10000 and was left on tissue sections overnight at 4 degrees Celsius. Secondary antibody was donkey anti-chicken conjugated to Alexa 647. Image from a verified customer review.

Immunocytochemistry/ Immunofluorescence: GFP Antibody [NB100-1614] -

Immunocytochemistry/ Immunofluorescence: GFP Antibody [NB100-1614] - Macrophages regulate dormancy in tumor cells.a Representative image of triple immunofluorescently stained in E0771-GFP primary tumor tissue for tumor cells, macrophages, & NR2F1. Green = GFP; Red = NR2F1; White = IBA-1; Blue = DAPI. White arrow shows a macrophage. The yellow arrow contact between an NR2F1-positive tumor cell & a macrophage. Mϕ=Macrophage. Scale bar=20 μm. b Quantification showing frequency of distances between NR2F1+ tumor cells to nearest macrophage in primary tumor. Data is normalized to frequency of distances between all DAPI+ nuclei to nearest TMEM. Bar = mean. Error bars = ±SEM. n = 34 fields of view (551 × 316 µm2) in 4 animals. For comparison between 0 & 200 µm bins a two-tailed Mann-Whitney test used (p < 0.0001). ****p < 0.0001. c Representative immunofluorescence images of NR2F1 expression in E0771-GFP tumor cells cultured alone, in direct contact w/ BAC1.2F5 macrophages,/in direct contact w/ HUVEC endothelial cells. White arrows show macrophages/endothelial cells in direct contact w/ a tumor cell. Green = GFP; Red = NR2F1; Blue = DAPI. TC = Tumor Cell. Mϕ = Macrophage. EC = Endothelial Cell. Scale bar = 15 μm. d Percentage of NR2F1-positive tumor cells from each group in C. TC alone: n = 777 cells in 9 independent experiments; TC+Mϕ; n = 226 cells in 6 independent experiments, TC+EC = n = 359 cells in 4 independent experiments. Bar = mean. Error bars = ±SEM. For TC vs. TC+Mϕ (p = 0.0039), & for TC vs. TC+EC (p = 1), a two-tailed Kruskal-Wallis test w/ Dunn’s multiple comparisons adjustment used. For TC+Mϕ vs. TC+EC (0.012), a two-tailed one-way ANOVA w/ Sidak’s multiple comparison adjustment used. *p < 0.05. **p < 0.01; ns = not significant. Source data are provided as a Source Data file. Image collected & cropped by CiteAb from following publication (https://pubmed.ncbi.nlm.nih.gov/35110548), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: GFP Antibody [NB100-1614] -

Immunocytochemistry/ Immunofluorescence: GFP Antibody [NB100-1614] - Spontaneously metastasizing tumor cells survive significantly longer at the secondary site compared to intravenously injected tumor cells.a Representative intravital microscopy images showing the possible fates of extravascular disseminated tumor cells in the lung parenchyma. Top: Images of disseminated tumor cells just after extravasation. Bottom left: Example of an extravascular tumor cell, which has died, as evidenced by small extravascular apoptotic bodies (yellow arrow). Bottom middle: Example of an extravascular tumor cell that survived as a single & solitary tumor cell over time. Bottom right: Example of an extravascular tumor cell that began to divide & grow into a micro-metastasis. Red = tdTomato labeled endothelial cells & 155 kDa Tetramethylrhodamine dextran labeled blood serum, Green = GFP labeled tumor cells. Yellow dashed lines delineate blood vessel boundaries. Scale bar = 15 μm. b Percentage of extravascular E0771-GFP disseminated tumor cells that died, survived, or grew after extravasation in EM & SM models 64 hrs after arrival to the lung vasculature. EM: n = 27 tumor cells in 4 mice. SM: n = 31 tumor cells in 4 mice. Bar = mean. Error bars = ±SEM. For Died & Survived columns, a two-tailed unpaired t-test was used (p = 0.0003 & 0.0005, respectively). For Grew columns, a two-tailed Mann-Whitney test was used (p = 0.14). ***p < 0.001. ns = not significant. Source data are provided as a Source Data file. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35110548), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: GFP Antibody [NB100-1614] -

Immunocytochemistry/ Immunofluorescence: GFP Antibody [NB100-1614] - Qx protects against ototoxin-induced HC death & promotes supporting cell proliferation. (A–I) TUNEL assay (red) performed in zebrafish incubated w/ vehicle or 300 µM of Qx alone (controls) or w/ corresponding ototoxin w/ or w/out Qx 300 µM. Animals counterstained w/ phalloidin (green). (A) Neomycin (Neo) 200 µM incubation for 30 min. (B) Gentamicin (GM) 50 µM incubation for 1 hour. (C) Cisplatin (CP) 400 µM incubation for 2 hrs. (D) GM 50 µM incubation for 1 hour followed by recovery for 5 hrs. (E) Incubation w/ Qx 300 µM for 8 hrs & Neo 200 µM for 30 min. (F) Incubation w/ Qx 300 µM for 8 hrs & GM 50 µM for 1 hour. (G) Qx 300 µM for 8 hrs + CP 400 µM for 2 hrs. (H) Qx 300 µM incubation for 8 hrs + GM 50 µM for 1 hour followed by 5 hrs recovery. Asterisks denote TUNEL-positive HCs. (I) The % of TUNEL-positive neuromasts calculated for each treatment & represented as mean +/− SEM. (J–R) Proliferation assays performed in 5dpf Tg(brn3c:GFP) in presence/absence of Qx & corresponding ototoxin, by BrdU-labelling method (red). Animals immunostained for GFP (green). (J) control. (K) Neo 200 µM 30 min. (L) GM 50 µM 1 hour. (M) CP: 400 µM 2 hrs. (N) Qx 300 µM 8 hrs. (O) Qx 300 µM 8 hrs + Neo 200 µM 30 min. (P) Qx 300 µM 8 hrs + GM 50 µM 1 hour. (Q) Qx 300 µM 8 hrs + CP 400 µM 2 hrs. Asterisks denote neuromast supporting cells positive for BrdU. (R) The % of BrdU-positive supporting cells per neuromast calculated for each treatment & represented as mean +/− SEM. One-way ANOVA, *p < 0.05, **p < 0.01. Black asterisks compared versus corresponding control. Red asterisk compared versus corresponding ototoxin-only treatment. Scale bar: (A–H) 10 µm, (J–O) 7 μm. Data taken from at least 15 animals & 3 experiments runs. Image collected & cropped by CiteAb from following publication (https://pubmed.ncbi.nlm.nih.gov/30310154), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: GFP Antibody [NB100-1614] -

Immunocytochemistry/ Immunofluorescence: GFP Antibody [NB100-1614] - Spontaneously metastasizing tumor cells are more frequently doubly positive for dormancy & stem-like markers compared to intravenously injected tumor cells.a Representative images of triple immunofluorescence staining for GFP, NR2F1, & SOX9 expression in primary tumors, circulating tumor cells (CTCs), & disseminated tumor cells (Lung) from an E0771-GFP SM model (Left) & in disseminated tumor cells (Lung) from an EM model (Right). Green = GFP; Red = NR2F1; Orange = SOX9; Blue = DAPI. Scale bar for Primary Tumor = 50 μm. Scale bar for CTCs & Lung = 15 μm. b Percentage of double-positive tumor cells NR2F1-positive SOX9High from each group in Fig. 5a. Primary Tumor: n = 2383 in 97 fields of view (65 × 65 µm2) in 7 animals; CTCs: n = 379 cells in 8 animals; SM Lung: n = 104 cells in 9 animals; In vitro: n = 413 cells in 3 independent experiments. EM Lung: n = 75 cells in 7 animals. Bar = mean. Error bars = ±SEM. For EM Lung vs. SM Lung (p = 0.0001) & EM Lung vs. in vitro (p = 0.69), a two-tailed Kruskal-Wallis test with Dunn’s multiple comparisons adjustment was used. For PT vs. CTC: (p = 0.0041), PT vs. Lung SM (p = 0.0030), & CTC vs. Lung SM (p = 1.00) a two-tailed ANOVA test with Sidak’s multiple comparisons adjustment was used. **p < 0.01. ***p < 0.001. ns = not significant. Source data are provided as a Source Data file. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35110548), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: GFP Antibody [NB100-1614] -

Immunocytochemistry/ Immunofluorescence: GFP Antibody [NB100-1614] - Dose protection curve against aminoglycosides. 5dpf larvae were incubated with vehicle (E3, A) or with 50 μM (D–F), 150 μM (G–I) or 300 μM (J–L) of Qx for a total of 8 hours. Gentamicin (GM, 50 μM, B,E,H,K) or neomycin (Neo, 200 µM,C,F,I,L) were added during the last 60 min or 30 min of incubation, respectively. Animals were fixed & stained for otoferlin (red) & GFP (green). (M) Quantification of the number of hair cells per neuromast after the different treatments represented as mean +/− SEM. Note that since no significant differences were found in the number of hair cells per neuromast when animals were incubated with the different Qx concentrations (0–300 µM, A,D,G,J), the control value represents the average of all these treatments. One-way ANOVA, Dunnett post test. *p < 0.05, **p < 0.01, ***p < 0.001. Black asterisks compared versus control. Red asterisks compared versus the corresponding aminoglycoside-only treatment. (N) Scores for neuromast morphology (see Materials & Methods). Scale bar: 7 μm. Data were taken from at least 20 animals & 3 experiments runs. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30310154), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: GFP Antibody [NB100-1614] -

Immunocytochemistry/ Immunofluorescence: GFP Antibody [NB100-1614] - Qx protects against cisplatin ototoxicity. 5dpf Tg(brn3c:GFP) larvae were incubated with vehicle alone (DMSO, A), 400 μM of cisplatin (CP, B), pre-treated with Qx for 2 hours & then incubated with CP for 6 hours (Qx, CP, C,E,G) or pre-treated with Qx for 2 hours & then co-treated with Qx & CP for 6 more hours (Qx + CP, D,F,H). Animals were fixed & immunostained for GFP (green) & otoferlin (red). (I) Quantification of the number of hair cells per neuromast after the different treatments represented as mean +/− SEM. One-way ANOVA, Dunnett post test. *p < 0.05, ***p < 0.001. Black asterisks compared versus control. Red asterisks compared versus CP 400 µM. (J) Scores for neuromast morphology (see Materials & Methods). Scale bar: 6 μm. Data were taken from at least 20 animals & 3 experiments runs. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30310154), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: GFP Antibody [NB100-1614] -

Immunocytochemistry/ Immunofluorescence: GFP Antibody [NB100-1614] - Dose protection curve against CP. 5dpf Tg(brn3c:GFP) larvae were incubated with 50 µM to 800 µM of CP (A,C,E,G) for 6 hours or pre-treated with 300 µM of Qx for 2 hours & then co-treated with Qx & CP (50µM-800µM) for 6 hours (B,D,F,H). Animals were fixed & immunostained for GFP (green) & otoferlin (red). Control animals were exposed to vehicle alone (DMSO). (I) Quantification of the number of hair cells per neuromast after the different treatments represented as mean +/− SEM. One-way ANOVA, Dunnett post test. ***p < 0.001. Black asterisks compared versus DMSO-treated animals. Red asterisks compared versus the corresponding CP concentration. (J) Scores for neuromast morphology (see Materials & Methods). Scale bar: 6 μm. Data were taken from at least 20 animals & 3 experiments runs. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30310154), licensed under a CC-BY license. Not internally tested by Novus Biologicals.